| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 250.225 | 231.925 | 135.165 | 65.883 | 71.606 | 48.185 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 250.268 | 232.060 | 158.397 | 65.884 | 71.607 | 214.050 | 1.565 | 34 | 0 | 105 |
| Total Expenses - EUR | 254.378 | 228.374 | 166.352 | 100.500 | 102.935 | 82.793 | 4.661 | 4.495 | 4.676 | 3.994 |
| Gross Profit/Loss - EUR | -4.110 | 3.686 | -7.954 | -34.616 | -31.328 | 131.258 | -3.096 | -4.461 | -4.676 | -3.889 |
| Net Profit/Loss - EUR | -4.562 | 2.712 | -9.498 | -35.278 | -32.046 | 129.071 | -3.096 | -4.461 | -4.676 | -3.889 |
| Employees | 7 | 5 | 4 | 4 | 3 | 3 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Salix Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 46.870 | 43.613 | 36.155 | 29.329 | 28.868 | 26.957 | 24.014 | 22.750 | 21.347 | 19.901 |
| Current Assets | 75.586 | 53.150 | 39.114 | 32.220 | 27.675 | 102.073 | 2.673 | 1.214 | 1.700 | 1.749 |
| Inventories | 44.630 | 33.717 | 19.920 | 19.698 | 17.436 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 23.690 | 11.055 | 4.222 | 9.284 | 7.189 | 242 | 821 | 914 | 1.339 | 1.486 |
| Cash | 7.265 | 8.377 | 14.971 | 3.237 | 3.051 | 101.831 | 1.852 | 300 | 361 | 263 |
| Shareholders Funds | 48.738 | 40.053 | 28.078 | -7.716 | -39.612 | 90.209 | 26.694 | 22.316 | 17.572 | 13.585 |
| Social Capital | 45 | 45 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 74.058 | 57.324 | 47.716 | 69.536 | 96.720 | 38.820 | 0 | 1.649 | 5.475 | 8.066 |
| Income in Advance | 300 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Salix Pharm Srl